Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial
Authors:
- Juleen GayedJGJuleen Gayed
- Vishva BangadVBVishva Bangad
- Xia XuXXXia Xu
- Federico MensaFMFederico Mensa
- Mark CutlerMCMark Cutler
- Özlem TüreciÖTÖzlem Türeci
- Uǧur ŞahinUŞUǧur Şahin
- Kayvon ModjarradKMKayvon Modjarrad
- Kena A. SwansonKSKena A. Swanson
- Annaliesa S. AndersonAAAnnaliesa S. Anderson
- Alejandra GurtmanAGAlejandra Gurtman
- Nicholas KitchinNKNicholas Kitchin
Open Access
Abstract
We report neutralization titer data against contemporary SARS-CoV-2 sublineages from an ongoing, phase 2/3, open-label, clinical trial of a single dose (30 μg) of an Omicron XBB.1.5-adapted BNT162b2 monovalent mRNA vaccine. The trial included healthy participants who had received at least three previous doses of an mRNA vaccine authorized in the United States, with the most recent authorized vaccine dose being a bivalent Omicron BA.4/BA.5-adapted vaccine given at least 150 days before the study vaccination. In this analysis, Omicron XBB.1.5, BA.2.86, and JN.1 serum neutralizing titers were assessed at baseline and at 1 month after vaccination. Analyses were conducted in a subset of participants who were at least 18 years of age (N = 40) and who had evidence of previous SARS-CoV-2 infection. Immunogenicity was also evaluated in a group of participants who received bivalent BA.4/BA.5-adapted BNT162b2 in another study (ClinicalTrials.gov Identifier: NCT05472038) and who were matched demographically to the participants in the current trial. In this analysis, monovalent XBB.1.5-adapted BNT162b2 vaccine elicited higher XBB.1.5, BA.2.86, and JN.1 neutralizing titers than those elicited by bivalent BA.4/BA.5-adapted BNT162b2. Overall geometric mean fold rises in neutralizing titers from baseline to 1 month after vaccination were higher among participants who received XBB.1.5-adapted BNT162b2 than those who received bivalent BA.4/BA.5-adapted BNT162b2 for XBB.1.5 (7.6 vs. 5.6), slightly higher for JN.1 (3.9 vs. 3.5), and similar for BA.2.86 (4.8 vs. 4.9). ClinicalTrials.gov Identifier: NCT05997290.Keywords
All Related Versions
Funding Information
- Pfizer
- BioNTech
This publication has 19 references indexed in Scilit:
- Effectiveness of the 2023–2024 Formulation of the COVID-19 Messenger RNA VaccineClinical Infectious Diseases, 2024
- Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB–Containing VaccinesThe Journal of Infectious Diseases, 2024
- Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in SwedenThe Lancet Infectious Diseases, 2024
- Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation in Denmark: a national cohort studyThe Lancet Infectious Diseases, 2024
- Virological characteristics of the SARS-CoV-2 JN.1 variantThe Lancet Infectious Diseases, 2024
- Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressureThe Lancet Infectious Diseases, 2023
- Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccinationThe Lancet Infectious Diseases, 2023
- Estimates of SARS-CoV-2 Seroprevalence and Incidence of Primary SARS-CoV-2 Infections Among Blood Donors, by COVID-19 Vaccination Status — United States, April 2021–September 2022MMWR. Morbidity and Mortality Weekly Report, 2023
- Predicting the efficacy of variant-modified COVID-19 vaccine boostersNature Medicine, 2023
- Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infectionNature Communications, 2022